Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex

Document first published:
Page updated:
Topic:
,
Publication type:
This document describes the evidence that has been considered by NHS England in formulating a proposal to routinely commission everolimus for the specific group of patients with SEGAs which are not amenable to surgery.

Document

Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex

Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex

  • PDF
  • 287 KB
  • 16 pages